Use of Creon^® Micro in the treatment of exocrine pancreatic insufficiency in children with cystic fibrosis. Analysis of the impact on the budget.

Plavinski S. L.
Doctor of Medicine¹

Barinova A. N.
PhD, Assistant Professor, Chair for Family Medicine¹

1 - North-West State Medical University named after I.I. Mechnikov, Saint-Petersburg, Russia

15/04/2017

The article considers the problem of choosing the most appropriate drugs for replacement therapy of endocrine pancreatic insufficiency. The possible consequences for the budget of the Russian Federation of including in the VED lists a new drug for substitution therapy, Creon^® Micro, are assessed. Authors conclude that the widespread use of this drug will provide for significant budget savings while maintaining the effectiveness of treatment.

Cystic Fibrosis, Enzyme Therapy, Creon^® Micro, pancreatic enzymes, enteric-cleavage capsules

1. Gool, Kees Van, Richard Norman, Martin B. Delatycki, Jane Hall, and John Massie. «Understanding the Costs of Care for Cystic Fibrosis: An Analysis by Age and Health State.» Value in Health 16, no. 2 (2013): 345-55. doi:10.1016/j.jval.2012.12.003.

2. Mlčoch, Tomáš, Jiří Klimeš, Libor Fila, Věra Vávrová, Veronika Skalická, Marek Turnovec, Veronika Krulišová, Jitka Jirčíková, Dana Zemková, Klára Vilimovská Dědečková, Alena Bílková, Vladimíra Frühaufová, Lukáš Homola, Zuzana Friedmannová, Radovan Drnek, Pavel Dřevínek, Tomáš Doležal, and Milan Macek. «Cost-of-illness analysis and regression modeling in cystic fibrosis: a retrospective prevalence-based study.» The European Journal of Health Economics 18, no. 1 (2016): 73-82. doi:10.1007/s10198-015-0759-9.

3. Heimeshoff, Mareike, Helge Hollmeyer, Jonas Schreyögg, Oliver Tiemann, and Doris Staab. «Cost of Illness of Cystic Fibrosis in Germany.» PharmacoEconomics 30, no. 9 (2012): 763-77. doi:10.2165/11588870-000000000-00000.

4. Colombo, Carla, Valeria Daccò, Gianfranco Alicandro, Silvana Loi, Silvio Mazzi, Carlo Lucioni, and Roberto Ravasio. «Cost of Cystic Fibrosis: Analysis of Treatment Costs in a Specialized Center in Northern Italy.» Advances in Therapy 30, no. 2 (2013): 165-75. doi:10.1007/s12325-013-0008-5.

5. Steinkamp, G. «Relationship between nutritional status and lung function in cystic fibrosis: cross sectional and longitudinal analyses from the German CF quality assurance (CFQA) project.» Thorax 57, no. 7 (2002): 596-601. doi:10.1136/thorax.57.7.596.

6. Kashirskaya, Nataliya Y., Nikolay I. Kapranov, Suntje Sander-Struckmeier, and Vladimir Kovalev. «Safety and efficacy of Creon® Micro in children with exocrine pancreatic insufficiency due to cystic fibrosis.» Journal of Cystic Fibrosis 14, no. 2 (2015): 275-81. doi:10.1016/j.jcf.2014.07.006.

7. The register of patients with cystic fibrosis in the Russian Federation for the year 2015. Edited by E. I. Kondrateva, S. A. Krasovskij, A. Ju Voronkova et al. Moscow: Medpraktika-M, 2016.

8. Gardner, Timothy B., Jeffrey C. Munson, and Nancy E. Morden. «The FDA and Prescription Pancreatic Enzyme Product Cost.» The American Journal of Gastroenterology 109, no. 5 (2014): 624-25. doi:10.1038/ajg.2013.430.

9. Kashirskaya, A. Yu, and N. I. Kapranov. «Experience of therapy of exocrine pancreatic insufficiency in cystic fibrosis in Russia.» Rossijskij medicinskij zhurnal 19, no. 12 (2011): 737-41.

10. Kraisinger, Marijo, Guenther Hochhaus, Arlene Stecenko, Ellen Bowser, and Leslie Hendeles. «Clinical Pharmacology of Pancreatic Enzymes in Patients with Cystic Fibrosis andIn VitroPerformance of Microencapsulated Formulations.» The Journal of Clinical Pharmacology 34, no. 2 (1994): 158-66. doi:10.1002/j.1552-4604.1994.tb03981.x.

11. Kuhnelt P., Mundlos S., Adler G. «Einfluss der Pelletgroesse eines Pankreasenzympraeparates auf die duodenale lipolytische Aktivitaet» Zeitschrift für Gastroenterologie Vol. 29 (1991): 417-21.

12. Mossner J., Keim V. «Therapie mit Pankreasenzymen.» Deutsches Ärzteblatt International no. 34-35 (2011): 578–82.

13. Hendeles, Leslie. «Treatment Failure After Substitution of Generic Pancrelipase Capsules.» Jama 263, no. 18 (1990): 2459. doi:10.1001/jama.1990.03440180065033.

14. Maev, I. V., Yu A. Kucheryavyj, and I. V. Troshina. «Pharmacoeconomic indicators of substitution enzyme therapy of exocrine pancreatic insufficiency.» Klinicheskie perspektivy gastroehnterologii, gepatologii, no. 4 (2011): 18-25.

15. Taylor, C.j., R. Thieroff-Ekerdt, S. Shiff, L. Magnus, R. Fleming, and C. Gommoll. «Comparison of two pancreatic enzyme products for exocrine insufficiency in patients with cystic fibrosis.» Journal of Cystic Fibrosis 15, no. 5 (2016): 675-80. doi:10.1016/j.jcf.2016.02.010.

16. Kuhn R.J., Eyting S., Henniges F., Potthoff A. «In Vitro Comparison of Physical Parameters, Enzyme Activity, Acid Resistance, and pH Dissolution Characteristics of Enteric-Coated Pancreatic Enzyme Preparations: Implications for Clinical Variability and Pharmacy Substitution.» J Pediatr Pharmacol Ther. 2007 Apr;12(2):115-28. doi: 10.5863/1551-6776-12.2.115.

17. Graff G.R., Maguiness K., McNamara J. et al. «Efficacy and tolerability of a new formulation of pancrelipase delayed-release capsules in children aged 7 to 11 years with exocrine pancreatic insufficiency and cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled, two-period crossover, superiority study.» Clin Ther. 2010 Jan;32(1):89-103. doi: 10.1016/j.clinthera.2010.01.012.

18. Graff, Gavin R., John Mcnamara, James Royall, Steven Caras, and Kristin Forssmann. «Safety and Tolerability of a New Formulation of Pancrelipase Delayed-Release Capsules (CREON®) in Children Under Seven Years of Age with Exocrine Pancreatic Insufficiency due to Cystic Fibrosis.» Clinical Drug Investigation 30, no. 6 (2010): 351-64. doi:10.2165/11533390-000000000-00000.

19. Wooldridge, Jamie L., James E. Heubi, Rodolfo Amaro-Galvez, Steven R. Boas, Kathryn V. Blake, Samya Z. Nasr, Barbara Chatfield, Susanna A. Mccolley, Marlyn S. Woo, Karen A. Hardy, Richard M. Kravitz, Cristina Straforini, Marco Anelli, and Candace Lee. «EUR-1008 pancreatic enzyme replacement is safe and effective in patients with cystic fibrosis and pancreatic insufficiency.» Journal of Cystic Fibrosis 8, no. 6 (2009): 405-17. doi:10.1016/j.jcf.2009.07.006.

20. Toskes, Phillip P., Angelo Secci, and Ruth Thieroff-Ekerdt. «Efficacy of a Novel Pancreatic Enzyme Product, EUR-1008 (Zenpep), in Patients With Exocrine Pancreatic Insufficiency Due to Chronic Pancreatitis.» Pancreas 40, no. 3 (2011): 376-82. doi:10.1097/mpa.0b013e31820b971c.

21. Kashirskaya, N. Yu, N. I. Kapranov, and Yu I. Vasileva. «Pharmacoeconomic efficiency of some modern therapy methods in children with cystic fibrosis.» Pediatricheskaya farmakologiya 3, no. 3 (2006): 32-37.

22. Asherova, I. K., N. Yu Kashirskaya, and N. I. Kapranov. «Comparison of efficacy and safety of Ermytal and Creon preparations in equivalent doses in patients with cystic fibrosis with insufficient exocrine pancreatic function.» Vestnik novyh medicinskih tekhnologij XIX, no. 2 (2012): 94-96.

23. Orlov, A. V., M. I. Nikitina, A. A. Nikitina, and V. N. Kovalev. «Efficacy and safety of the mini-tablet pancreatin Pangrol 10 000 units and 25 000 units in patients with cystic fibrosis.» Pediatr VII, no. 1 (2016): 22-26.